Skip to content

IVM Versus Standard IVF in Infertile Patients Diagnosed With PCOS

In Vitro Maturation Versus Standard in Vitro Fertilization in Infertile Patients Diagnosed With Polycystic Ovaries Syndrome: a Study Protocol for a Single-center Prospective, Randomized Controlled Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03463772
Enrollment
350
Registered
2018-03-13
Start date
2018-03-16
Completion date
2020-10-31
Last updated
2019-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PCOS

Keywords

in vitro maturation, polycystic ovarian syndrome, oocyte

Brief summary

A single center, prospective, open-label, non-inferiority randomized controlled clinical trials (1:1 treatment ratio) regarding pregnancy outcomes between IVM and standard IVF among infertility couples with PCOS in China.

Detailed description

A single center, randomized controlled clinical trial will enroll 350 couples with PCOS undergoing their first cycle of IVF. The participation in this study will be approximately 2 years with a total of 7 visits from the cycle beginning, pregnancy to delivery. On day 2 or day 3 following the onset of menstrual bleeding, eligible patients will be allocated to two groups at a ratio of 1:1- IVM protocol, and standard IVF protocol. All participants will be randomized through stratified block randomization according to the study sites.

Interventions

PROCEDUREstandard IVF

Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be inseminated using ICSI or conventional IVF according to the seman analysis. All embryos will be cultured to blastocyst stage and be vitrified.

Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.

Sponsors

Jie Qiao
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Eligible patients that have provided informed consent will be randomized to either IVM or standard IVF. Randomization and allocation of patients to study groups will be performed on the day 2 or 3 of the menstrual cycle. Randomization will be centrally controlled by administrative staff in the trial center, who are not involved in the treatment procedure. When there is an eligible participant to be enrolled into the study, nurses from the specific site will log in the trial center to get allocation of patients according to a computer-generated randomization list in a 1:1 ratio, with a variable block size of 2, 4 or 8 and stratified by center.

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 38 Years
Healthy volunteers
No

Inclusion criteria

1. Infertile couples scheduled for their first IVF cycle. 2. Women diagonosed with polycystic ovarian syndrome. 3. Voluntary participation and informed consent obtained.

Exclusion criteria

1. Couple with contraindication for IVF or ICSI. 2. Couples receiving donor sperm or donor eggs. 3. Couples with indications or have plan to receive PGD and PGS. 4. Sperm analysis diagnosed as azoospermia; 5. Either male partner or female partner with an abnormal chromosome karyotype (chromosome polymorphisms was not included). 6. Women who have undergone unilateral ovariectomy.

Design outcomes

Primary

MeasureTime frameDescription
the proportion of ongoing pregnancy leading to live birthafter 22 weeks of gestationnumber of ongoing pregnancy leading to live birth resulting from the first oocyte retrieval cycle after the randomization ( 6 month) divided by the number of patients with oocyte retrieval

Secondary

MeasureTime frameDescription
clinical pregnancy7 weeks after embryo transferone or more observed gestational sac or definitive clinical signs of pregnancy under ultrasonography at 7 weeks after embryo transfer (including clinical documented ectopic pregnancy)
Miscarriage28 weeks of gestationSpontaneous loss of an intra-uterine pregnancy prior to 28 completed weeks of gestational age
Preterm birth28-37 weeks of pregnancyBirth of a fetus delieved after 28 and before 37 completed weeks of gestational age in participants confirmed ongoing pregnancy
Birth weightwithin 2 weeks after live birthIncluding low birth weight (defined as weight \<2500 gm at birth), very low birth weight (defined as \< 1500 gm at birth), high birth weight (defined as \> 4000 gm at birth) and very high birth weight (defined as \> 4500 gm at birth).
implantation28 days after embryo transferNumber of gestational sacs observed per embryo transferred
Small for gestational agewithin 2 weeks after live birthLess than 10th centile for gestational age at delivery based on standardised ethnicity based charts.
Congenital anomalywithin 2 weeks after live birthAny congenital anomaly will be included diagnosed by physical examinition, ultrasound or necessary testing (including CT, X-ray etc.)
Perinatal mortalitywithin 2 weeks after live birthFetal or neonatal death occurring during late pregnancy (at 28 completed weeks of gestational age and later), during childbirth, or up to seven completed days after birth.
Moderate/severe ovarian hyperstimulation syndrome (OHSS)From date of controlled ovarian hyperstimulation until the date of oocyte retrieval, assesses about 14-16 days.exaggerated systemic response to ovarian stimulation characterized by a wide spectrum of clinical and laboratory manifestations. It is classified as mild, moderate, or severe according to the degree of abdominal distention, ovarian enlargement and respiratory hemodynamic, and metabolic complications. Diagosised by ultrasound, blood testing and physical examination according the Chinese Medical Guildline.
Large for gestational agewithin 2 weeks after live birthBirth weight \>90th centile for gestation, based on standardised ethnicity based charts.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 29, 2026